A synthesis of 53 recently added cannabis articles — key themes, clinical context, and Dr. Caplan’s take.
In the Mix: 23 More Articles — March 04, 2026
23 cannabis articles scored below the CED clinical relevance threshold in the last 24 hours. Summaries and source links included.
Daily Digest: Last 24 Hours: Adolescent Risk, Aging Brains, and the Slow March Toward Pharmaceutical-Grade Cannabis — March 04, 2026
Last 24 Hours March 04, 2026 — 41 articles reviewed This cycle’s coverage clustered around two poles of the age spectrum, with a single study in Pediatrics reinforcing that even infrequent adolescent...
In the Mix: 15 More Articles — March 04, 2026
15 cannabis articles reviewed and scored below the CED clinical relevance threshold in the March 04, 2026 feed update. Organized by topic with summaries and source links.
Linnea Achieves CEP Certification for Cannabidiol Isolate – Morningstar
WHY IT MATTERS: Patients and clinicians who rely on CBD-based treatments may eventually benefit from greater confidence in product consistency and purity as pharmaceutical-grade certification raises the quality floor across the industry. CLINICAL OVERVIEW: CEP certification from the European Directorate for the Quality of Medicines represents one of the highest regulatory benchmarks a pharmaceutical ingredient can achieve, confirming that a substance meets strict standards for identity, purity, and manufacturing consistency. For cannabidiol isolate, achieving this designation signals a meaningful shift toward pharmaceutical-grade quality control in cannabinoid production, moving the ingredient closer to the standards required for approved drug formulations rather than supplement-grade products.
Medical cannabis delivery app seeing growth in the DMV and Jamaica | DC News Now
WHY IT MATTERS: Patients with debilitating conditions who struggle to travel to dispensaries may soon have more reliable, regulated delivery options that make consistent access to their recommended cannabis products genuinely feasible. CLINICAL OVERVIEW: Medical cannabis delivery services represent a meaningful evolution in how patients access their medicine, particularly for those with mobility limitations, chronic illness, or conditions that make visiting a dispensary physically difficult. As regulatory frameworks in various jurisdictions begin to accommodate telehealth consultations and home delivery, the logistical gap between a physician’s recommendation and a patient actually receiving their medicine is narrowing.
Patient Protect launches to tackle discrimination against UK medical cannabis patients
WHY IT MATTERS: If you are a UK medical cannabis patient, dedicated legal support services are now available to help you challenge discrimination in employment, housing, and policing situations that may arise from your prescription. CLINICAL OVERVIEW: Medical cannabis patients in the United Kingdom continue to face real-world consequences that extend well beyond their clinical care, including discrimination in housing decisions, workplace policies, law enforcement encounters, and driving eligibility assessments. These challenges arise because legal frameworks and institutional policies have not kept pace with the formal recognition of medical cannabis as a legitimate prescribed treatment.
Study Published in Pediatrics Finds Infrequent Cannabis Use Can Impact Adolescent …
WHY IT MATTERS: Parents and teens should understand that occasional cannabis use is not a safe middle ground during adolescence, as even infrequent exposure appears linked to real academic and emotional consequences. CLINICAL OVERVIEW: Research published in Pediatrics reinforces longstanding clinical concern that adolescent cannabis exposure does not require heavy or daily use to produce measurable harm. Even low-frequency use, occurring as rarely as once monthly, appears associated with worse academic outcomes and disruptions in emotional regulation and mental health.
Study finds no links between cannabis use and cognitive decline or dementia in older people
WHY IT MATTERS: Older adults who use cannabis for pain, sleep, or anxiety can share this research with their physicians to support more informed, evidence-based conversations about risk rather than assumption-based discouragement. CLINICAL OVERVIEW: Concerns about cannabis use accelerating cognitive decline or contributing to dementia risk in older adults have long influenced clinical conversations, but emerging research is beginning to challenge those assumptions. The biological reality is complex, given that the endocannabinoid system plays a regulatory role in neuroinflammation and neuroprotection, and that older adults are using cannabis for legitimate symptom management at increasing rates.
Kansas Democrats push cannabis decriminalization, GOP leadership blocks a vote – KWCH
✦ New CED Clinical Relevance #45 Clinical Context Background information relevant to the evolving cannabis medicine landscape. Policy Why This Matters Clinicians in Kansas need to understand that cannabis remains fully criminalized...